Human epidermal growth factor receptor 2 in combined hepatocellular-cholangiocarcinoma: Prognostic and predictive guide for adjuvant chemotherapy

Table 3 Clinicopathological characteristics of patients in the human epidermal growth factor receptor 2 negative group after propensity score matching

Characteristic	Median (IQR) or n (%)		P value
	Chemotherapy group (n = 13)	Non-chemotherapy group (n = 26)
Sex			0.713
Male	8 (61.5)	19 (73.1)
Female	5 (38.5)	7 (26.9)
Age	52.0 (47.0-63.5)	56.5 (51.8-62.3)	0.290
HBV			0.837
Present	9 (69.2)	15 (57.7)
Absent	4 (30.8)	11 (42.3)
Liver cirrhosis			0.378
Present	2 (15.4)	9 (34.6)
Absent	11 (84.6)	17 (65.4)
ALB (g/L)	45.6 (39.6-48.6)	42.3 (39.2-44.6)	0.104
TBIL (μmol/L)	17.7 (12.9-20.6)	14.9 (12.1-21.3)	0.870
PT (seconds)	10.7 (10.5-11.5)	11.1 (10.8-11.5)	0.241
AFP (ng/mL)			0.183
> 40	2 (15.4)	11 (42.3)
≤ 40	11 (84.6)	15 (57.7)
Satellite lesions			0.852
Present	2 (15.4)	2 (7.7)
Absent	11 (84.6)	24 (92.3)
Microvascular invasion			1.000
Present	1 (7.7)	2 (7.7)
Absent	12 (9.23)	24 (92.3)
Macrovascular invasion			0.883
Present	3 (23.1)	4 (15.4)
Absent	10 (76.9)	22 (84.6)
Lymphatic node metastasis			0.852
Present	2 (15.4)	2 (7.7)
Absent	11 (84.6)	24 (92.3)
Maximum tumor diameter (cm)			1.000
≤ 5	7 (53.8)	14 (53.8)
> 5	6 (46.2)	12 (46.2)
CA19-9 (U/mL)			0.254
≤ 25	9 (69.2)	13 (50.0)
> 25	4 (30.8)	13 (50.0)
Histological grade			0.904
High/median	5 (38.5)	8 (30.8)
Low	8 (61.5)	18 (69.2)
TLS score			0.234
3	2 (15.4)	3 (11.5)
2	1 (7.7)	4 (15.4)
1	0	4 (15.4)
0	10 (76.9)	15 (57.7)

IQR: Interquartile ranges; CA19-9: Carbohydrate antigen 19-9; HBV: Hepatitis B virus; ALB: Albumin; TBIL: Total bilirubin; PT: Prothrombin time; AFP: Alpha-fetoprotein; TLS: Tertiary lymphoid structures.